CJC-1295: growth hormone
CJC-1295 makes a hormone signal last. Its most precise human findings concern blood, leaving a harder question about the body beyond it.
What is CJC-1295?
CJC-1295 is a synthetic growth hormone releasing hormone analog, built on the first 29 amino acids of the natural releasing signal. It stimulates the GHRH receptor on the pituitary's growth-hormone-producing cells. The liver then responds to growth hormone by producing IGF-1.
The chemistry solves a practical problem: the natural peptide is broken down quickly. Four amino-acid substitutions help the analog resist degradation. In the long-acting DAC form, an added chemical handle makes a covalent bond to circulating albumin, a blood protein. The albumin-conjugate experiments in rats and in vitro established the design before the human studies.
I admire that bit of engineering. There is also a naming trap: Modified GRF 1-29, often called CJC-1295 without DAC, lacks the albumin-binding handle and is short-acting. Applying the DAC trial's multi-day figures to that other molecule loses the reason the figures exist.
Healthy-adult studies
In the early studies in healthy adults aged 21 to 61, CJC-1295 produced two- to ten-fold increases in mean growth hormone for six days or more. IGF-1 rose one-and-a-half- to three-fold for nine to eleven days after a single administration and remained above baseline for up to 28 days after repeated administrations. The estimated peptide half-life was 5.8 to 8.1 days.
A separate study of healthy men aged 20 to 40 examined growth hormone pulsatility. One week later, trough growth hormone was approximately 7.5-fold higher, mean growth hormone was about 46% higher and IGF-1 about 45% higher. The frequency and magnitude of the pulses were unaltered. Pulsatility means the hormone continued to arrive in bursts despite the prolonged stimulation.
These are unusually clear pharmacological results. I remain less satisfied by the way they acquire a physique in retelling: the healthy-adult studies measured hormone behaviour, with strength and body-composition outcomes still unestablished.
Serum proteins
A study in 11 healthy young men followed changes in serum proteins. Apolipoprotein A1 and a transthyretin form decreased; a C-terminal albumin fragment and immunoglobulin and beta-haemoglobin species increased. The immunoglobulin and albumin-fragment signals correlated linearly with IGF-1.
I relish the move from hormone concentrations to an inventory of serum proteins. The authors were identifying candidate biomarkers of hormone-system activation. A changed protein profile is evidence of a biological response, with its significance for health requiring further work.
Body weight in GHRH-deficient mice
There is a growth result, in a very particular animal. Mice unable to make GHRH regained normal body weight and length with CJC-1295; less frequent administration in that experiment was progressively less effective, and pituitary growth hormone messenger RNA increased.
Restoring an absent releasing signal gives that experiment its force. A healthy adult seeking more muscle begins in a different physiological condition. The comparison page places this mouse finding beside the human studies without treating the populations as interchangeable.
Clinical history
CJC-1295 has no approved human indication anywhere. Its original long-acting development programme was discontinued after entering Phase 2 in HIV-associated visceral obesity. A patient death is frequently mentioned in that history; the public record does not establish that CJC-1295 caused it.
The review of GHRH and its analogues places long-acting designs in their wider pharmacological context. FDA's 2024 briefing materials raised immunogenicity, the possibility of an immune response to the peptide, among the concerns behind not recommending CJC-1295 for the Section 503A compounding bulks list.
Sustained growth hormone exposure can promote sodium and water retention and reduce insulin sensitivity. Higher circulating IGF-1 has an epidemiological association with certain cancers; that association leaves compound-specific causation unanswered. There are no large or long-term trials in healthy adults establishing CJC-1295's safety or efficacy.
Online accounts report sleep changes, recovery, a leaner appearance, swelling, tingling, headache, fatigue, local reactions and upward blood-sugar drift. These are anecdotes rather than clinical evidence, with uncertain material and frequent co-use. My patience with claims about a desirable body runs out well before those reports can settle the risks.